Selskabets formål er at drive virksomhed ved fremstilling og salg af kemiske, farmaceutiske samt veterinærmedicinske produkter.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 784 mio. | 6.3 mio. | 365.2 mio. | 23.2 mio. | 125000 | |
CVR: 14450807
Secondary names: BOEHRINGER INGELHEIM A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 41183144
CVR 35451307
CVR 36392398
CVR 14479880
CVR 37626619
The financial health of BOEHRINGER INGELHEIM DANMARK A/S shows signs of instability, with a notable decline in profit despite a significant increase in revenue in 2024, reaching 783,971,000 DKK but only generating a profit of 6,342,000 DKK. Over the past few years, revenue has generally trended upwards, from 400,040,000 DKK in 2021 to 783,971,000 DKK in 2024, although profit has fluctuated, peaking at 14,386,000 DKK in 2020 before declining in subsequent years. The company's equity position has also deteriorated, dropping from 39,890,000 DKK in 2023 to 23,232,000 DKK in 2024, raising concerns about its financial stability and ability to sustain operations. Positioned within the pharmaceutical wholesale and healthcare sector, the company faces challenges in maintaining profitability and managing its equity effectively.
AI-generated summary
companydata.dk